KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Capital Employed (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Capital Employed for 15 consecutive years, with 0.21% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 7.0% to 0.21% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.21% through Dec 2025, down 7.0% year-over-year, with the annual reading at 0.22% for FY2025, 9.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.21% at Halozyme Therapeutics, down from 0.57% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.57% in Q3 2025, with the low at 0.15% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.24% recorded in 2024.
  • Peak annual rise in Return on Capital Employed hit 45bps in 2021, while the deepest fall reached -84bps in 2021.
  • Over 5 years, Return on Capital Employed stood at 0.27% in 2021, then plummeted by -42bps to 0.16% in 2022, then grew by 28bps to 0.2% in 2023, then soared by 42bps to 0.28% in 2024, then decreased by -24bps to 0.21% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.21%, 0.57%, and 0.34% for Q4 2025, Q3 2025, and Q2 2025 respectively.